Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business. Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to help meet the diverse health care needs of patients and their families and caregivers. We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd., which has a strong and lasting commitment to the U.S. market. Our heritage and mission have earned us recognition as an innovative, efficient, solution-oriented pharmaceutical company - a company that effectively works with healthcare professionals, hospitals and managed care organizations to develop and market specialty products that help address unmet needs. Our ability to forge strong alliances gives us a competitive edge. In the United States, our rapid growth and strong performance result from putting patients and their families first when making decisions and from empowering the people who manage our operations. Eisai employees personify our values of integrity, respect, professionalism, quality and teamwork. As you continue exploring our corporate web site, you will learn more about how our commitment to hhc is a motivating force for everything we do and everything we produce..
Type
Public
HQ
Woodcliff Lake, US
Founded
1941
Size (employees)
10,495 (est)
Eisai was founded in 1941 and is headquartered in Woodcliff Lake, US

Eisai Office Locations

Eisai has an office in Woodcliff Lake
Woodcliff Lake, US (HQ)
100 Tice Blvd
Show all (1)

Eisai Financials and Metrics

Eisai Financials

USD

Market capitalization (31-Oct-2017)

15.9 b

Closing share price (31-Oct-2017)

55.3
Eisai's current market capitalization is $15.9 b.
Show all financial metrics

Eisai Market Value History

Eisai Median Salaries

Source: 36 public H-1B filings from Eisai

Eisai's Web-traffic and Trends

Eisai Online and Social Media Presence

Eisai News and Updates

Insomnia Medication Market increasing demand with Leading key players: Eisai, Merck, Pfizer, Sanofi, Takeda

HTF MI published a new industry research that focuses on Insomnia Medication market and delivers in-depth market analysis and future prospects of China Insomnia Medication market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Chagas Disease Management Market 2018 Global Analysis,Opportunities and Forecasts to 2023

WiseGuyReports.Com Publish a New Market Research Report On –“ Chagas Disease Management Market 2018 Global Analysis,Opportunities and Forecasts to 2023”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Acute Myeloid Leukemia Therapeutics Market: Applications and Global Markets

eukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Posted via Industry Today. Follow us on Twitter @IndustryToday

Upper GI Series Market Worldwide Breath-Taking Revenue by Top Key Players Forecasts Till 2027

Global Upper GI Series Market Analysis by application (esophageal reflux, esophageal varices, Ulcers, Hiatal hernias & others), by test types (the standard barium upper GI series & double-contrast upper GI series) & by end users (hospitals, clinics & laboratories): forecast to 2027 P…

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Bristol-Myers Squibb’s Opdivo is currently the only immuno-oncology treatment approved to treat kidney cancer—but yet another pair of rivals is now moving in to threaten that status.

Acute Myeloid Leukemia (AML) Therapeutics Market Size will Escalate Rapidly in the Near Future (2017 - 2025)

The global acute myeloid leukemia (AML) therapeutics market is anticipated to show lucrative growth owing to increased investment in innovative technologies by key players. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Eisai Company Life and Culture

You may also be interested in